Dhat syndrome, a culture-bound syndrome, is associated with anxiety, somatic, and mood symptoms related to semen loss, commonly in males and uncommonly in females, associated with vaginal discharge. Only one case report has been described in the past with Dhat delusions associated with schizophrenia. In this case report, we describe two cases of somatic delusional disorder with Dhat-like content and paranoid personality traits. who initially presented with classical symptoms of Dhat syndrome. Dhat syndrome may present as a prodromal manifestation of a psychotic illness. Further studies are needed to explore which at-risk patients presenting with Dhat syndrome may present with psychotic symptoms in the future.
{"title":"Dhat delusion in individuals with paranoid personality traits: A case series","authors":"D. Banerjee","doi":"10.17816/cp15510","DOIUrl":"https://doi.org/10.17816/cp15510","url":null,"abstract":"Dhat syndrome, a culture-bound syndrome, is associated with anxiety, somatic, and mood symptoms related to semen loss, commonly in males and uncommonly in females, associated with vaginal discharge. Only one case report has been described in the past with Dhat delusions associated with schizophrenia. In this case report, we describe two cases of somatic delusional disorder with Dhat-like content and paranoid personality traits. who initially presented with classical symptoms of Dhat syndrome. Dhat syndrome may present as a prodromal manifestation of a psychotic illness. Further studies are needed to explore which at-risk patients presenting with Dhat syndrome may present with psychotic symptoms in the future.","PeriodicalId":262442,"journal":{"name":"Consortium Psychiatricum","volume":"556 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140245275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Y. Elsherif, Saria Gouher, Mutaz Mohsin Abualhab, Joseph El-Khoury
BACKGROUND: Cannabis Hyperemesis Syndrome (CHS) is a condition characterized by episodic bursts of vomitingand abdominal pain linked to cannabis use. The clinical picture mimics an acute abdomen and is often misdiagnosed,especially when the patient avoids reporting their cannabis use for legal reasons.CASE REPORT: We report on the case of a 33-year-old man that was brought to the emergency room with a history of3 days of non-bloody, non-projectile, and non-bilious brownish vomit, coupled with severe epigastric and left hypochondriacpain, and a slight fever. He was a daily cannabis user for several years and had stopped using a week or so before theonset of the symptoms, as he was traveling to a country with more restrictive cannabis laws. His condition deterioratedrapidly, followed by emergency room attendance, thorough diagnostic work-up, and unsuccessful interventions, includingintravenous treatment with the anti-emetic Ondansetron. The patient was referred to a psychiatrist after a suspectedpsychogenic etiology by the medical team. The history was suggestive of CHS and also included anxious, depressedmood with ‘brain fog’. The abdominal pain was the most severe complaint. A combination of tramadol, promethazine,and mirtazapine given on an outpatient basis led to full recovery within 10 days.CONCLUSION: CHS can occur soon after the interruption of chronic cannabis use and overlap with withdrawal symptom.A combination of anti-histaminergic, opioid-based medication, and antidepressant mirtazapine seemed an effectivetreatment of CHS, which resulted in a relatively quick recovery.
{"title":"Cannabis Hyperemesis Syndrome in a Recently Abstinent Chronic User: Assessment and Intervention","authors":"Y. Elsherif, Saria Gouher, Mutaz Mohsin Abualhab, Joseph El-Khoury","doi":"10.17816/cp15473","DOIUrl":"https://doi.org/10.17816/cp15473","url":null,"abstract":"BACKGROUND: Cannabis Hyperemesis Syndrome (CHS) is a condition characterized by episodic bursts of vomitingand abdominal pain linked to cannabis use. The clinical picture mimics an acute abdomen and is often misdiagnosed,especially when the patient avoids reporting their cannabis use for legal reasons.CASE REPORT: We report on the case of a 33-year-old man that was brought to the emergency room with a history of3 days of non-bloody, non-projectile, and non-bilious brownish vomit, coupled with severe epigastric and left hypochondriacpain, and a slight fever. He was a daily cannabis user for several years and had stopped using a week or so before theonset of the symptoms, as he was traveling to a country with more restrictive cannabis laws. His condition deterioratedrapidly, followed by emergency room attendance, thorough diagnostic work-up, and unsuccessful interventions, includingintravenous treatment with the anti-emetic Ondansetron. The patient was referred to a psychiatrist after a suspectedpsychogenic etiology by the medical team. The history was suggestive of CHS and also included anxious, depressedmood with ‘brain fog’. The abdominal pain was the most severe complaint. A combination of tramadol, promethazine,and mirtazapine given on an outpatient basis led to full recovery within 10 days.CONCLUSION: CHS can occur soon after the interruption of chronic cannabis use and overlap with withdrawal symptom.A combination of anti-histaminergic, opioid-based medication, and antidepressant mirtazapine seemed an effectivetreatment of CHS, which resulted in a relatively quick recovery.","PeriodicalId":262442,"journal":{"name":"Consortium Psychiatricum","volume":"11 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139961046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BACKGROUND: The Diagnostic Classification of Mental Health and Developmental Disorders of Infancy and Early Childhood (DC:0-5TM) is widely used in many Western countries. For Russian specialists, such classification represents a relatively new tool for the comprehensive diagnosis of mental disorders in children from birth to the five-year-old threshold. The purpose for presenting this case study report is to showcase the practical application of the DC:0-5TM. AIM: This study aims to illustrate the diagnostic process according to the DC:0-5TM criteria using the example of a specific clinical case report involving the collaborative efforts of two specialists: a child psychiatrist and a clinical child psychologist. METHODS: DC:0-5TM consists of five axes. The main axis focuses on clinical diagnosis criteria for mental disorders, considering their age specificity. The remaining four axes allow one to take into account and specify data related to biological, social, and psychological factors, which play a crucial role in understanding the causes and characteristics of a mental disorder in a child. RESULTS: In the examined case, an analysis of symptoms by means of the Clinical Disorders axis revealed that they were consistent with the diagnostic criteria for autism spectrum disorder. The use of the remaining axes supplemented the clinical diagnosis with specific details about the adverse physical health factors in the child, a high cumulative stress burden, significant developmental delays in the emotional, speech, and social dimensions, as well as dysfunction in the mother-child dyad. Since the parents declined medication for their son, this information proved crucial in developing a support program for both the child and the family. CONCLUSION: The comprehensive diagnostic approach using the DC:0-5TM axes proved highly effective, not only in psychiatric diagnosis but also in establishing goals and objectives for subsequent intervention. Its application in psychiatric, clinical psychology, and corrective educational practices has the potential to make support for children in their early years a more personalized and family-oriented undertaking.
{"title":"The interdisciplinary diagnostics of autism spectrum disorder using DC:0-5TM — a case report","authors":"G. V. Skoblo, S. V. Trushkina","doi":"10.17816/cp14783","DOIUrl":"https://doi.org/10.17816/cp14783","url":null,"abstract":"BACKGROUND: The Diagnostic Classification of Mental Health and Developmental Disorders of Infancy and Early Childhood (DC:0-5TM) is widely used in many Western countries. For Russian specialists, such classification represents a relatively new tool for the comprehensive diagnosis of mental disorders in children from birth to the five-year-old threshold. The purpose for presenting this case study report is to showcase the practical application of the DC:0-5TM. \u0000AIM: This study aims to illustrate the diagnostic process according to the DC:0-5TM criteria using the example of a specific clinical case report involving the collaborative efforts of two specialists: a child psychiatrist and a clinical child psychologist. \u0000METHODS: DC:0-5TM consists of five axes. The main axis focuses on clinical diagnosis criteria for mental disorders, considering their age specificity. The remaining four axes allow one to take into account and specify data related to biological, social, and psychological factors, which play a crucial role in understanding the causes and characteristics of a mental disorder in a child. \u0000RESULTS: In the examined case, an analysis of symptoms by means of the Clinical Disorders axis revealed that they were consistent with the diagnostic criteria for autism spectrum disorder. The use of the remaining axes supplemented the clinical diagnosis with specific details about the adverse physical health factors in the child, a high cumulative stress burden, significant developmental delays in the emotional, speech, and social dimensions, as well as dysfunction in the mother-child dyad. Since the parents declined medication for their son, this information proved crucial in developing a support program for both the child and the family. \u0000CONCLUSION: The comprehensive diagnostic approach using the DC:0-5TM axes proved highly effective, not only in psychiatric diagnosis but also in establishing goals and objectives for subsequent intervention. Its application in psychiatric, clinical psychology, and corrective educational practices has the potential to make support for children in their early years a more personalized and family-oriented undertaking.","PeriodicalId":262442,"journal":{"name":"Consortium Psychiatricum","volume":"55 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138592989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Zhilyaeva, G. Rukavishnikov, Elvira Aleksandrovna Manakova, G. E. Mazo
BACKGROUND: Recently a significant part of schizophrenia studies have been focused on the role of cytokines, especially interleukin-6 (IL-6). Some authors have suggested a pathogenetic role for IL-6 in schizophrenia and concluded that therapy that centers on suppressing IL-6 activity may prove beneficial for certain categories of patients with the disorder. However, many questions about whether the changes in IL-6 levels in schizophrenia are primary, related to symptoms or caused by therapy, are concomitant metabolic disorders, are related to smoking or other secondary factors remain unanswered.AIM: To assess the level of serum IL-6 in patients with schizophrenia in comparison with healthy controls, as well as to study its association with clinical and socio-demographic characteristics.METHODS: Some 125 patients with schizophrenia and 95 healthy volunteers were examined. The evaluation of IL-6 was performed by enzyme immunoassay. All patients were assessed using standardized psychometric instruments. Information from patient medical records on the course of the disease and treatment was analyzed.RESULTS: The level of IL-6 was significantly higher in the patients than in the healthy volunteers (z=2.58; p=0.0099), but among men the difference between the patients and volunteers was not significant. Statistically significant correlations were found between the level of serum IL-6 and the severity of the cognitive impairment of patients: [auditory (ρ=–0.31; p=0.00063) and working memory (ρ=−0.25; p=0.0065), hand-eye coordination (ρ=−0.29; p=0.0011), verbal fluency (ρ=−0.28; p=0.0019) and problem-solving capacity (ρ=−0.22; p=0.013)], total severity of schizophrenia symptoms (PANSS, ρ=0.22; p=0.016), PANSS positive subscale (ρ=0.18; p=0.048), and the age of manifestation (ρ=0.20; p=0.025) and disease duration (ρ=0.18; p=0.043). The level of IL-6 was the lowest in patients treated with third-generation antipsychotics, and the highest in those treated with a first-generation antipsychotics (H=6.36; p=0.042). Moreover, the level of IL-6 was significantly higher in inpatients than in outpatients and daycare hospitals (H=18.59; p=0.0001).CONCLUSION: The study confirmed that there there are associations between the serum IL-6 level and schizophrenia, the age of the patient, duration of the disease and how late in one's life cycle it began manisfesting itself, as well as a number of clinical characteristics. Considering that IL-6 is associated with a wide range of symptoms that are loosely controlled by antipsychotics, this biochemical marker needs to be studied to look into how closely its level tracks with an unfavorable course of schizophrenia. That would require further prospective studies.
{"title":"Serum interleukin-6 in schizophrenia: associations with clinical and sociodemographic characteristics","authors":"T. Zhilyaeva, G. Rukavishnikov, Elvira Aleksandrovna Manakova, G. E. Mazo","doi":"10.17816/cp11067","DOIUrl":"https://doi.org/10.17816/cp11067","url":null,"abstract":"BACKGROUND: Recently a significant part of schizophrenia studies have been focused on the role of cytokines, especially interleukin-6 (IL-6). Some authors have suggested a pathogenetic role for IL-6 in schizophrenia and concluded that therapy that centers on suppressing IL-6 activity may prove beneficial for certain categories of patients with the disorder. However, many questions about whether the changes in IL-6 levels in schizophrenia are primary, related to symptoms or caused by therapy, are concomitant metabolic disorders, are related to smoking or other secondary factors remain unanswered.AIM: To assess the level of serum IL-6 in patients with schizophrenia in comparison with healthy controls, as well as to study its association with clinical and socio-demographic characteristics.METHODS: Some 125 patients with schizophrenia and 95 healthy volunteers were examined. The evaluation of IL-6 was performed by enzyme immunoassay. All patients were assessed using standardized psychometric instruments. Information from patient medical records on the course of the disease and treatment was analyzed.RESULTS: The level of IL-6 was significantly higher in the patients than in the healthy volunteers (z=2.58; p=0.0099), but among men the difference between the patients and volunteers was not significant. Statistically significant correlations were found between the level of serum IL-6 and the severity of the cognitive impairment of patients: [auditory (ρ=–0.31; p=0.00063) and working memory (ρ=−0.25; p=0.0065), hand-eye coordination (ρ=−0.29; p=0.0011), verbal fluency (ρ=−0.28; p=0.0019) and problem-solving capacity (ρ=−0.22; p=0.013)], total severity of schizophrenia symptoms (PANSS, ρ=0.22; p=0.016), PANSS positive subscale (ρ=0.18; p=0.048), and the age of manifestation (ρ=0.20; p=0.025) and disease duration (ρ=0.18; p=0.043). The level of IL-6 was the lowest in patients treated with third-generation antipsychotics, and the highest in those treated with a first-generation antipsychotics (H=6.36; p=0.042). Moreover, the level of IL-6 was significantly higher in inpatients than in outpatients and daycare hospitals (H=18.59; p=0.0001).CONCLUSION: The study confirmed that there there are associations between the serum IL-6 level and schizophrenia, the age of the patient, duration of the disease and how late in one's life cycle it began manisfesting itself, as well as a number of clinical characteristics. Considering that IL-6 is associated with a wide range of symptoms that are loosely controlled by antipsychotics, this biochemical marker needs to be studied to look into how closely its level tracks with an unfavorable course of schizophrenia. That would require further prospective studies.","PeriodicalId":262442,"journal":{"name":"Consortium Psychiatricum","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139224675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
There is an error occurred in the article Schizophrenia: a narrative review of etiological and diagnostic issues published in the Consortium Psychiatricum journal (Volume 3 Issue 3) by Sofia Oskolkova. Due to a technical error on authors and editorial parts and without any malicious intent, the Errors in diagnostics of schizophrenia chapter links to incorrect references.
The publisher made changes to the electronic version of the published article (PDF and HTML) on the journals website instead of the version with errors.
The authors team and the editorial board of the journal are sure that the mistakes could not significantly affect the perception and interpretation of the published work by readers, and should not become the reason for retraction.The authors team and the editorial board apologize to the readers for the mistakes made.
Sofia Oskolkova在《精神病学联合会杂志》(第3卷第3期)上发表的文章《精神分裂症:病因学和诊断问题的叙述性回顾》中出现了一个错误。由于作者和编辑部分的技术错误，没有任何恶意，“精神分裂症诊断中的错误”章节链接到错误的参考文献。
出版商在期刊网站上修改了已发表文章的电子版(PDF和HTML)，而不是有错误的版本。
作者团队和期刊编委会确信，这些错误不会显著影响读者对已发表文章的认知和解读，不应成为撤稿的理由。作者团队和编辑委员会为所犯的错误向读者道歉。
{"title":"Corrigendum to “Schizophrenia: a narrative review of etiological and diagnostic issues” (Consortium Psychiatricum, 2022, Volume 3, Issue 3, doi: 10.17816/CP132)","authors":"Sofia N. Oskolkova","doi":"10.17816/cp13625","DOIUrl":"https://doi.org/10.17816/cp13625","url":null,"abstract":"There is an error occurred in the article Schizophrenia: a narrative review of etiological and diagnostic issues published in the Consortium Psychiatricum journal (Volume 3 Issue 3) by Sofia Oskolkova. Due to a technical error on authors and editorial parts and without any malicious intent, the Errors in diagnostics of schizophrenia chapter links to incorrect references.
 The publisher made changes to the electronic version of the published article (PDF and HTML) on the journals website instead of the version with errors.
 The authors team and the editorial board of the journal are sure that the mistakes could not significantly affect the perception and interpretation of the published work by readers, and should not become the reason for retraction.The authors team and the editorial board apologize to the readers for the mistakes made.","PeriodicalId":262442,"journal":{"name":"Consortium Psychiatricum","volume":"92 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136272413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BACKGROUND: The use of remote forms of mental health care has become widespread during the period of epidemiological restrictions due to the COVID-19 pandemic. Methodological and organizational issues remain insufficiently developed, including the level of equivalence of the use of telemedicine technologies in the diagnosis of autistic spectrum disorders.
AIM: Study of the equivalence of diagnostic tools in the framework of telemedicine and face-to-face consultations in children with autistic spectrum disorders according to modern scientific literature.
METHODS: A descriptive review of scientific studies published between January 2017 and May 2023 was carried out. The papers presented in the electronic databases PubMed, Web of Science, and eLibrary were analyzed. Descriptive analysis was used to summarize the obtained data.
RESULTS: The conducted analysis convincingly indicates sufficient equivalence of remote tools used in different countries for level I screening, assessment scales, and structured procedures for diagnosing autistic spectrum disorders with a high level of specificity from 60.0 to 94.4%, sensitivity from 75 dog 98.4%, and satisfaction of patients and their legal representatives.
CONCLUSION: The widespread use of validated telemedicine diagnostic systems in clinical practice contributes to the early detection of autistic spectrum disorders, increasing the timeliness and effectiveness of medical, corrective psychological, pedagogical, and habilitation interventions.
背景:由于COVID-19大流行，在流行病学限制期间，远程精神卫生保健形式的使用已变得普遍。方法和组织问题仍然没有充分发展，包括在诊断自闭症谱系障碍中使用远程医疗技术的等效水平。
目的:根据现代科学文献，研究自闭症谱系障碍儿童远程医疗和面对面会诊框架下诊断工具的等效性。
方法:对2017年1月至2023年5月间发表的科学研究进行描述性综述。对电子数据库PubMed、Web of Science和library中的论文进行分析。采用描述性分析对所得数据进行总结。
结果:所进行的分析令人信服地表明，不同国家用于一级筛查、评估量表和诊断自闭症谱系障碍的结构化程序的远程工具具有足够的等效性，特异性从60.0到94.4%，敏感性从75狗到98.4%，患者及其法律代表的满意度很高。
结论:在临床实践中广泛使用经过验证的远程医疗诊断系统有助于早期发现自闭症谱系障碍，提高医学、矫正心理、教学和康复干预的及时性和有效性。
{"title":"Equivalence of the Autism Spectrum Disorders Diagnostics in Children in Telemedicine and Face-to-Face Consultations: A 
 erature Review","authors":"Oleg Zamilievich Khayretdinov, Lyusiena Igorevna Rubakova","doi":"10.17816/cp12496","DOIUrl":"https://doi.org/10.17816/cp12496","url":null,"abstract":"BACKGROUND: The use of remote forms of mental health care has become widespread during the period of epidemiological restrictions due to the COVID-19 pandemic. Methodological and organizational issues remain insufficiently developed, including the level of equivalence of the use of telemedicine technologies in the diagnosis of autistic spectrum disorders.
 AIM: Study of the equivalence of diagnostic tools in the framework of telemedicine and face-to-face consultations in children with autistic spectrum disorders according to modern scientific literature.
 METHODS: A descriptive review of scientific studies published between January 2017 and May 2023 was carried out. The papers presented in the electronic databases PubMed, Web of Science, and eLibrary were analyzed. Descriptive analysis was used to summarize the obtained data.
 RESULTS: The conducted analysis convincingly indicates sufficient equivalence of remote tools used in different countries for level I screening, assessment scales, and structured procedures for diagnosing autistic spectrum disorders with a high level of specificity from 60.0 to 94.4%, sensitivity from 75 dog 98.4%, and satisfaction of patients and their legal representatives.
 CONCLUSION: The widespread use of validated telemedicine diagnostic systems in clinical practice contributes to the early detection of autistic spectrum disorders, increasing the timeliness and effectiveness of medical, corrective psychological, pedagogical, and habilitation interventions.","PeriodicalId":262442,"journal":{"name":"Consortium Psychiatricum","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135132007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jyoti Prakash Sahoo, N Simple Santi, Birendra Naik Narayan
As one of the largest contributors of morbidity and mortality, psychiatric disorders are anticipated to triple in prevalence over the coming decade or so. Major obstacles to psychiatric care include stigma, funding constraints, and a dearth of resources and psychiatrists. The main thrust of our present-day discussion has been towards the direction of how machine learning and artificial intelligence could influence the way that patients experience care. To better grasp the issues regarding trust, privacy, and autonomy, their societal and ethical ramifications need to be probed. There is always the possibility that the artificial mind could malfunction or exhibit behavioral abnormalities. An in-depth philosophical understanding of these possibilities in both human and artificial intelligence could offer correlational insights into the robotic management of mental disorders in the future. This article looks into the role of artificial intelligence, the different challenges associated with it, as well as the perspectives in the management of such mental illnesses as depression, anxiety, and schizophrenia.
{"title":"The Future of Psychiatry with Artificial Intelligence: Can the Man-Machine Duo Redefine the Tenets?","authors":"Jyoti Prakash Sahoo, N Simple Santi, Birendra Naik Narayan","doi":"10.17816/cp13626","DOIUrl":"https://doi.org/10.17816/cp13626","url":null,"abstract":"As one of the largest contributors of morbidity and mortality, psychiatric disorders are anticipated to triple in prevalence over the coming decade or so. Major obstacles to psychiatric care include stigma, funding constraints, and a dearth of resources and psychiatrists. The main thrust of our present-day discussion has been towards the direction of how machine learning and artificial intelligence could influence the way that patients experience care. To better grasp the issues regarding trust, privacy, and autonomy, their societal and ethical ramifications need to be probed. There is always the possibility that the artificial mind could malfunction or exhibit behavioral abnormalities. An in-depth philosophical understanding of these possibilities in both human and artificial intelligence could offer correlational insights into the robotic management of mental disorders in the future. This article looks into the role of artificial intelligence, the different challenges associated with it, as well as the perspectives in the management of such mental illnesses as depression, anxiety, and schizophrenia.","PeriodicalId":262442,"journal":{"name":"Consortium Psychiatricum","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135132025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abdul Qadir Jilani, ARISH KHAN, SALONI SALONI, SESHAN KUMAR, JAI SINGH, KUSHAGRA VARMA, ALEEM SIDDIQUI, REEMA SINHA
BACKGROUND: The COVID-19 global pandemic exposed gaps in the treatment of common physical and mental disorders that had to do with things like lockdowns, poor convenience, fear of contracting COVID, and economic constraints. Hence, to address these treatment gaps while also limiting exposure to the COVID-19 infection, telemedicine in the form of telephone and internet consultations has increasingly become the recourse around the world. Our center adopted this trend and also launched a telepsychiatry initiative in order to better cater to the needs of patients with pre-existing mental health disorders and to ensure regular follow-ups and compliance with prescription regiments.
AIM: The present study aimed to assess the level of patient satisfaction with the online psychiatric services/telepsychiatry.
METHODS: The sample consisted of 100 patients with pre-existing mental health disorders. This was a cross-sectional study lasting 6 months. The DigiDoc app by Hospital Information Software (HIS) software, which is used to manage a patients appointment schedule, relevant clinical and lab details, along with follow-up prescriptions, was used to follow the selected patients for the purpose of this study. This software also provides a digital platform for video calls for online consultation. The Client Satisfaction Questionnaires-8 (CSQ-8) was employed to collect patient data for analysis.
RESULTS: The mean total CSQ-8 score of the study sample was 21.015.80 (832), which corresponds to a low-to-moderate level of satisfaction with online psychiatric services/telepsychiatry. Most patients (45%) reported low satisfaction levels, followed by 37% who reported moderate levels of satisfaction. Only 18% of patients reported higher satisfaction with telepsychiatry.
CONCLUSION: Despite the psychiatrists ability to provide adequate professional advice and psychoeducation through online psychiatric services, patients level of satisfaction proved moderate-to-low. This suggests a need to design standard protocols and guidelines in the search and provision of consultation services on online psychiatric service platforms that could help enhance patients levels of satisfaction.
{"title":"Level of Patient Satisfaction with Online Psychiatric Outdoor Services","authors":"Abdul Qadir Jilani, ARISH KHAN, SALONI SALONI, SESHAN KUMAR, JAI SINGH, KUSHAGRA VARMA, ALEEM SIDDIQUI, REEMA SINHA","doi":"10.17816/cp5597","DOIUrl":"https://doi.org/10.17816/cp5597","url":null,"abstract":"BACKGROUND: The COVID-19 global pandemic exposed gaps in the treatment of common physical and mental disorders that had to do with things like lockdowns, poor convenience, fear of contracting COVID, and economic constraints. Hence, to address these treatment gaps while also limiting exposure to the COVID-19 infection, telemedicine in the form of telephone and internet consultations has increasingly become the recourse around the world. Our center adopted this trend and also launched a telepsychiatry initiative in order to better cater to the needs of patients with pre-existing mental health disorders and to ensure regular follow-ups and compliance with prescription regiments.
 AIM: The present study aimed to assess the level of patient satisfaction with the online psychiatric services/telepsychiatry.
 METHODS: The sample consisted of 100 patients with pre-existing mental health disorders. This was a cross-sectional study lasting 6 months. The DigiDoc app by Hospital Information Software (HIS) software, which is used to manage a patients appointment schedule, relevant clinical and lab details, along with follow-up prescriptions, was used to follow the selected patients for the purpose of this study. This software also provides a digital platform for video calls for online consultation. The Client Satisfaction Questionnaires-8 (CSQ-8) was employed to collect patient data for analysis.
 RESULTS: The mean total CSQ-8 score of the study sample was 21.015.80 (832), which corresponds to a low-to-moderate level of satisfaction with online psychiatric services/telepsychiatry. Most patients (45%) reported low satisfaction levels, followed by 37% who reported moderate levels of satisfaction. Only 18% of patients reported higher satisfaction with telepsychiatry.
 CONCLUSION: Despite the psychiatrists ability to provide adequate professional advice and psychoeducation through online psychiatric services, patients level of satisfaction proved moderate-to-low. This suggests a need to design standard protocols and guidelines in the search and provision of consultation services on online psychiatric service platforms that could help enhance patients levels of satisfaction.","PeriodicalId":262442,"journal":{"name":"Consortium Psychiatricum","volume":"37 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135132026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BACKGROUND: Computational psychiatry is an area of scientific knowledge which lies at the intersection of neuroscience, psychiatry, and computer science. It employs mathematical models and computational simulations to shed light on the complexities inherent to mental disorders.
AIM: The aim of this narrative review is to offer insight into the current landscape of computational psychiatry, to discuss its significant challenges, as well as the potential opportunities for the fields growth.
METHODS: The authors have carried out a narrative review of the scientific literature published on the topic of computational psychiatry. The literature search was performed in the PubMed, eLibrary, PsycINFO, and Google Scholar databases. A descriptive analysis was used to summarize the published information on the theoretical and practical aspects of computational psychiatry.
RESULTS: The article relates the development of the scientific approach in computational psychiatry since the mid-1980s. The data on the practical application of computational psychiatry in modeling psychiatric disorders and explaining the mechanisms of how psychopathological symptomatology develops (in schizophrenia, attention-deficit/hyperactivity disorder, autism spectrum disorder, anxiety disorders, obsessive-compulsive disorder, substance use disorders) are summarized. Challenges, limitations, and the prospects of computational psychiatry are discussed.
CONCLUSION: The capacity of current computational technologies in psychiatry has reached a stage where its integration into psychiatric practice is not just feasible but urgently needed. The hurdles that now need to be addressed are no longer rooted in technological advancement, but in ethics, education, and understanding.
{"title":"Current Status, Challenges and Future Perspectives in Computational Psychiatry: A narrative review","authors":"Kirill Fedorovich Vasilchenko, Egor Maksimovich Chumakov","doi":"10.17816/cp11244","DOIUrl":"https://doi.org/10.17816/cp11244","url":null,"abstract":"BACKGROUND: Computational psychiatry is an area of scientific knowledge which lies at the intersection of neuroscience, psychiatry, and computer science. It employs mathematical models and computational simulations to shed light on the complexities inherent to mental disorders.
 AIM: The aim of this narrative review is to offer insight into the current landscape of computational psychiatry, to discuss its significant challenges, as well as the potential opportunities for the fields growth.
 METHODS: The authors have carried out a narrative review of the scientific literature published on the topic of computational psychiatry. The literature search was performed in the PubMed, eLibrary, PsycINFO, and Google Scholar databases. A descriptive analysis was used to summarize the published information on the theoretical and practical aspects of computational psychiatry.
 RESULTS: The article relates the development of the scientific approach in computational psychiatry since the mid-1980s. The data on the practical application of computational psychiatry in modeling psychiatric disorders and explaining the mechanisms of how psychopathological symptomatology develops (in schizophrenia, attention-deficit/hyperactivity disorder, autism spectrum disorder, anxiety disorders, obsessive-compulsive disorder, substance use disorders) are summarized. Challenges, limitations, and the prospects of computational psychiatry are discussed.
 CONCLUSION: The capacity of current computational technologies in psychiatry has reached a stage where its integration into psychiatric practice is not just feasible but urgently needed. The hurdles that now need to be addressed are no longer rooted in technological advancement, but in ethics, education, and understanding.","PeriodicalId":262442,"journal":{"name":"Consortium Psychiatricum","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135132181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yana Morozova, Vladimir Smirnov, Igor Makarov, Darya Emelina
ABSTRACT
BACKGROUND: Interest in the issue of childhood autism has surged in the recent decades. At the same time, despite the significant progress achieved in understanding the etiological and pathogenetic aspects of the condition, effective ways to treat it have continued to elude us. Stem cell therapy appears to hold great promise in the treatment and rehabilitation of patients with both neurological diseases (cerebral palsy, hydrocephalus) and mental disorders (autism, schizophrenia).
METHODS: This article presents a case report describing the use of nucleated cord blood cells in a patient with regressive autism and resistance to standard therapies. The childs condition was assessed before treatment and 6 and 12 months after.
RESULTS: Clinical observation, psychometric, and instrumental diagnostic methods led to a significant improvement in the childs condition in the form of perception development, reduction of somatosensory disorders, normalization of emotional status, and a development of social and communication skills.
CONCLUSION: We assume that the result obtained may be associated with the normalization of the immunological status of our patient thanks to the cord blood cells therapy and consider it necessary to conduct further studies into the effectiveness of the method, taking the pathogenic mechanisms of autism into account.
{"title":"The Use of Umbilical Cord Blood Nucleated Cells in the Treatment of Regressive Autism: A Clinical Case Report","authors":"Yana Morozova, Vladimir Smirnov, Igor Makarov, Darya Emelina","doi":"10.17816/cp9300","DOIUrl":"https://doi.org/10.17816/cp9300","url":null,"abstract":"ABSTRACT
 BACKGROUND: Interest in the issue of childhood autism has surged in the recent decades. At the same time, despite the significant progress achieved in understanding the etiological and pathogenetic aspects of the condition, effective ways to treat it have continued to elude us. Stem cell therapy appears to hold great promise in the treatment and rehabilitation of patients with both neurological diseases (cerebral palsy, hydrocephalus) and mental disorders (autism, schizophrenia).
 METHODS: This article presents a case report describing the use of nucleated cord blood cells in a patient with regressive autism and resistance to standard therapies. The childs condition was assessed before treatment and 6 and 12 months after.
 RESULTS: Clinical observation, psychometric, and instrumental diagnostic methods led to a significant improvement in the childs condition in the form of perception development, reduction of somatosensory disorders, normalization of emotional status, and a development of social and communication skills.
 CONCLUSION: We assume that the result obtained may be associated with the normalization of the immunological status of our patient thanks to the cord blood cells therapy and consider it necessary to conduct further studies into the effectiveness of the method, taking the pathogenic mechanisms of autism into account.","PeriodicalId":262442,"journal":{"name":"Consortium Psychiatricum","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135926111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：